Through recombinant DNA technology, the final lysine and proline residues on the C-terminal end of the B-chain are reversed. This modification does not alter receptor binding, but blocks the formation of insulin dimers and hexamers. This allows larger amounts of active monomeric insulin to be immediately available for postprandial injections.
Insulin lispro
Insulin glulisine
Insulin aspart
Insulin detemir
Insulin glargine
Lente insulin
Insulin degludec
Insulin degludec/liraglutide